Person · CIK 1697616

Erick Lucera

Chief Financial Officer at Dyne Therapeutics; director at SAB Biotherapeutics and Beyond Air; EVP at Editas Medicine

Earlier: Bone Biologics, Aveo Pharmaceuticals and Valeritas Holdings

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$361K

Noticed on Form 144$501K

Bought on Form 4$66K

Companies7

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Dyne Therapeutics DYN	Common Stock	Directly	119,766	Aug 13, 2026 · Filing · EDGAR
Dyne Therapeutics DYN	Stock Option (Right to Buy) exercise $16.00, expires Feb 11, 2036, into Common Stock	Directly	105,000	Feb 12, 2026 · Filing · EDGAR
SAB Biotherapeutics SABS	Stock option (right to buy) exercise $3.99, expires Dec 16, 2035, into Common Stock	Directly	150,000	Dec 16, 2025 · Filing · EDGAR
Beyond Air AITB	Common Stock	Directly	43,608	Aug 14, 2024 · Filing · EDGAR
Beyond Air AITB	Stock Options (Right to buy) exercise $1.95, into Common Stock	Directly	3,750	Nov 4, 2025 · Filing · EDGAR
Editas Medicine EDIT	Common Stock	Directly	112,720	Mar 4, 2025 · Filing · EDGAR
Editas Medicine EDIT	Stock Option (right to buy) exercise $1.72, expires Mar 7, 2035, into Common Stock	Directly	275,100	Mar 8, 2025 · Filing · EDGAR
Editas Medicine EDIT	Stock Option (right to buy) exercise $1.72, expires Mar 7, 2035, into Common Stock	Directly	70,000	Mar 8, 2025 · Filing · EDGAR
Bone Biologics	Non-Employee Stock Option exercise $0.64, expires Sep 13, 2033, into Common Stock	Directly	85,763	Sep 18, 2023 · Filing · EDGAR
Bone Biologics	Non-Employee Stock Option exercise $48.41, expires Aug 23, 2027, into Common Stock	Directly	1,229	Sep 18, 2023 · Filing · EDGAR
Bone Biologics	Non-Employee Stock Option exercise $157.50, expires Oct 15, 2031, into Common Stock	Directly	677	Sep 18, 2023 · Filing · EDGAR
Bone Biologics	Non-Employee Stock Option exercise $105.60, expires Jan 1, 2032, into Common Stock	Directly	291	Sep 18, 2023 · Filing · EDGAR
Bone Biologics	Non-Employee Stock Option exercise $157.50, expires Oct 26, 2031, into Common Stock	Directly	99	Sep 18, 2023 · Filing · EDGAR
Valeritas Holdings	Common Stock	Directly	4,500	May 22, 2017 · Filing · EDGAR
Valeritas Holdings	Employee Stock Option (Right to Buy) exercise $0.43, expires Mar 7, 2029, into Common Stock	Directly	280,000	Mar 7, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q3 2026	$47K	$47K	—
Q2 2026	$181K	$181K	—
Q1 2025	$7K	$15K	—
Q3 2024	—	—	$15K
Q2 2024	$125K	$257K	—
Q1 2023	—	—	$14K
Q2 2017	—	—	$7K
Q1 2017	—	—	$30K

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Dyne Therapeutics DYN · Stifel Nicolaus & Company · No 10b5-1 plan stated · 4 notices
Aug 13, 2026	1,797 · ~$47K	Aug 13, 2026	Sold as noticed Sold 1,797 at $26.28 on Aug 13 · $47K Form 4	Filing · EDGAR
Jun 25, 2026	2,362 · ~$48K	Jun 25, 2026	Sold as noticed Sold 2,362 at $20.37 on Jun 25 · $48K Form 4	Filing · EDGAR
May 13, 2026	1,448 · ~$27K	May 13, 2026	Sold as noticed Sold 1,448 at $18.36 on May 13 · $27K Form 4	Filing · EDGAR
Apr 1, 2026	5,727 · ~$107K	Apr 1, 2026	Sold as noticed Sold 5,727 at $18.64 on Apr 1 · $107K Form 4	Filing · EDGAR
Editas Medicine EDIT · ETrade Financial · 10b5-1 plan adopted May 12, 2023 · 2 notices
Feb 28, 2025	8,000 · ~$15K	Mar 3, 2025	Partly sold Sold 4,109 at $1.71 on Mar 4 · $7K likely match Form 4	Filing · EDGAR
May 17, 2024	45,000 · ~$257K	May 17, 2024	Partly sold Sold 22,337 at $5.61 on May 20 · $125K likely match Form 4	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Dyne Therapeutics DYN Chief Financial Officer · filings 2025 to 2026 · sold $229K · $229K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 13, 2026	Sale under a 10b5-1 plan	−1,797	$26.28	$47K	119,766 direct	Filing · EDGAR
Jun 25, 2026	Open-market or private sale	−2,362	$20.37	$48K	121,563 direct	Filing · EDGAR
May 13, 2026	Sale under a 10b5-1 plan	−1,448	$18.36	$27K	123,925 direct	Filing · EDGAR
Apr 1, 2026	Sale under a 10b5-1 plan	−5,727	$18.64	$107K	125,373 direct	Filing · EDGAR
Feb 12, 2026	Grant or award from the company	+65,000			131,100 direct	Filing · EDGAR
Feb 12, 2026	Grant or award from the company Stock Option (Right to Buy)	+105,000			105,000 direct	Filing · EDGAR
Mar 31, 2025	Grant or award from the company	+66,100			66,100 direct	Filing · EDGAR
Mar 31, 2025	Grant or award from the company Stock Option (Right to Buy)	+214,500			214,500 direct	Filing · EDGAR

SAB Biotherapeutics SABS Director · filings 2023 to 2025

Date	Transaction	Shares	Held after	Source
Dec 16, 2025	Grant or award from the company Stock option (right to buy)	+150,000	150,000 direct	Filing · EDGAR
Jul 15, 2024	Grant or award from the company Stock Option (right to buy)	+20,000	20,000 direct	Filing · EDGAR
Apr 3, 2023	Grant or award from the company Employee Stock Option (right to buy)	+25,000	25,000 direct	Filing · EDGAR

Beyond Air AITB Director · filings 2018 to 2025 · bought $29K

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−2,250			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+2,250			2,250 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−2,000			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+2,000			2,000 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−1,500			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+1,500			1,500 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−1,250			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+1,250			1,250 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−1,250			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+1,250			1,250 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−1,000			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+1,000			1,000 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−1,250			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+1,250			1,250 direct	Filing · EDGAR
Nov 4, 2025	Returned to the company Stock Options (Right to buy)	−3,750			0 direct	Filing · EDGAR
Nov 4, 2025	Grant or award from the company Stock Options (Right to buy)	+3,750			3,750 direct	Filing · EDGAR
Mar 26, 2025	Grant or award from the company Stock Options (Right to buy)	+75,000			75,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−45,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+45,000			45,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−40,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+40,000			40,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−30,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+30,000			30,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−25,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+25,000			25,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−25,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+25,000			25,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−20,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+20,000			20,000 direct	Filing · EDGAR
Nov 22, 2024	Returned to the company Stock Options (Right to buy)	−25,000			0 direct	Filing · EDGAR
Nov 22, 2024	Grant or award from the company Stock Options (Right to buy)	+25,000			25,000 direct	Filing · EDGAR
Aug 14, 2024	Open-market or private purchase	+39,266	$0.39	$15K	43,608 direct	Filing · EDGAR
Mar 20, 2024	Grant or award from the company Stock Option (right to buy)	+45,000			45,000 direct	Filing · EDGAR
Mar 29, 2023	Grant or award from the company Stock Option (right to buy)	+40,000			40,000 direct	Filing · EDGAR
Mar 16, 2023	Open-market or private purchase	+2,000	$6.82	$14K	4,342 direct	Filing · EDGAR
Mar 3, 2022	Grant or award from the company Stock Option (right to buy)	+30,000			30,000 direct	Filing · EDGAR
Mar 4, 2021	Grant or award from the company Stock Option (right to buy)	+25,000			25,000 direct	Filing · EDGAR
Feb 16, 2021	Option or RSU exercised or converted	+1,171	$4.25	$5K	2,342 direct	Filing · EDGAR
Feb 16, 2021	Option or RSU exercised or converted Tranche B Warrant (Right to Buy)	−1,171			0 direct	Filing · EDGAR
Aug 13, 2018	Grant or award from the company Stock Option (right to buy)	+25,000			25,000 direct	Filing · EDGAR
Feb 16, 2018	Option or RSU exercised or converted	+1,171	$4.25	$5K	1,171 direct	Filing · EDGAR
Feb 16, 2018	Open-market or private purchase Tranche A Warrant (right to buy)	+1,171	$0.01	$12	1,171 direct	Filing · EDGAR
Feb 16, 2018	Open-market or private purchase Tranche B Warrant (right to buy)	+1,171	$0.01	$12	1,171 direct	Filing · EDGAR
Feb 16, 2018	Option or RSU exercised or converted Tranche A Warrant (right to buy)	−1,171			0 direct	Filing · EDGAR

Editas Medicine EDIT EVP, chief financial officer · filings 2023 to 2025 · sold $132K · $272K noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 8, 2025	Grant or award from the company Stock Option (right to buy)	+275,100			275,100 direct	Filing · EDGAR
Mar 8, 2025	Grant or award from the company Stock Option (right to buy)	+70,000			70,000 direct	Filing · EDGAR
Mar 4, 2025	Sale under a 10b5-1 plan	−4,109	$1.71	$7K	112,720 direct	Filing · EDGAR
May 20, 2024	Sale under a 10b5-1 plan	−22,337	$5.61	$125K	116,829 direct	Filing · EDGAR
Mar 2, 2024	Grant or award from the company	+35,300			113,200 direct	Filing · EDGAR
Mar 2, 2024	Grant or award from the company	+25,966			139,166 direct	Filing · EDGAR
Mar 2, 2024	Grant or award from the company Stock Option (right to buy)	+106,000			106,000 direct	Filing · EDGAR
May 17, 2023	Grant or award from the company	+77,900			77,900 direct	Filing · EDGAR
May 17, 2023	Grant or award from the company Stock Option (right to buy)	+155,800			155,800 direct	Filing · EDGAR

Bone Biologics Director · filings 2021 to 2023

Date	Transaction	Shares	Held after	Source
Sep 18, 2023	Grant or award from the company Non-Employee Stock Option	+85,763	85,763 direct	Filing · EDGAR
Aug 23, 2022	Grant or award from the company Non-Employee Stock Option	+36,845	68,516 direct	Filing · EDGAR
Jan 1, 2022	Grant or award from the company Non-Employee Stock Option	+8,722	31,671 direct	Filing · EDGAR
Oct 26, 2021	Grant or award from the company Non-Employee Stock Option	+2,949	22,949 direct	Filing · EDGAR

Aveo Pharmaceuticals Chief Financial Officer · filings 2020 to 2023

Date	Transaction	Shares	Held after	Source
Jan 19, 2023	Returned to the company Stock Option (Right to Buy)	−50,000	0 direct	Filing · EDGAR
Jan 19, 2023	Returned to the company Stock Option (Right to Buy)	−100,000	0 direct	Filing · EDGAR
Jan 19, 2023	Returned to the company Stock Option (Right to Buy)	−218,800	0 direct	Filing · EDGAR
Feb 15, 2022	Grant or award from the company Stock Option (right to buy)	+218,800	218,800 direct	Filing · EDGAR
Feb 5, 2021	Grant or award from the company Stock Option (right to buy)	+100,000	100,000 direct	Filing · EDGAR
Jan 6, 2020	Grant or award from the company Stock Option (right to buy)	+500,000	500,000 direct	Filing · EDGAR

Valeritas Holdings Chief Financial Officer · filings 2017 to 2019 · bought $37K

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 7, 2019	Grant or award from the company Employee Stock Option (Right to Buy)	+280,000			280,000 direct	Filing · EDGAR
Nov 19, 2018	Grant or award from the company Employee Stock Option (Right to Buy)	+363,000			363,000 direct	Filing · EDGAR
Feb 13, 2018	Grant or award from the company Employee Stock Option (Right to Buy)	+27,000			27,000 direct	Filing · EDGAR
May 22, 2017	Open-market or private purchase	+1,000	$4.95	$5K	4,000 direct	Filing · EDGAR
May 22, 2017	Open-market or private purchase	+500	$4.95	$2K	4,500 direct	Filing · EDGAR
Mar 23, 2017	Open-market or private purchase	+3,000	$10.00	$30K	3,000 direct	Filing · EDGAR
Mar 23, 2017	Grant or award from the company Employee Stock Option (Right to Buy)	+73,800			73,800 direct	Filing · EDGAR

All 51 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Aug 17, 2026	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Aug 13, 2026	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Jun 26, 2026	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Jun 25, 2026	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
May 14, 2026	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
May 13, 2026	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Apr 3, 2026	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Apr 1, 2026	Form 144	Dyne Therapeutics DYN	Filing · EDGAR
Feb 17, 2026	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Dec 18, 2025	Form 4	SAB Biotherapeutics SABS	Filing · EDGAR
Nov 6, 2025	Form 4	Beyond Air AITB	Filing · EDGAR
Apr 1, 2025	Form 4	Dyne Therapeutics DYN	Filing · EDGAR
Apr 1, 2025	Form 3	Dyne Therapeutics DYN	Filing · EDGAR
Mar 28, 2025	Form 4	Beyond Air AITB	Filing · EDGAR
Mar 27, 2025	Form 4	Editas Medicine EDIT	Filing · EDGAR
Mar 5, 2025	Form 4	Editas Medicine EDIT	Filing · EDGAR
Feb 28, 2025	Form 144	Editas Medicine EDIT	Filing · EDGAR
Nov 26, 2024	Form 4	Beyond Air AITB	Filing · EDGAR
Aug 15, 2024	Form 4	Beyond Air AITB	Filing · EDGAR
Jul 17, 2024	Form 4	SAB Biotherapeutics SABS	Filing · EDGAR
May 22, 2024	Form 4	Editas Medicine EDIT	Filing · EDGAR
May 17, 2024	Form 144	Editas Medicine EDIT	Filing · EDGAR
Mar 21, 2024	Form 4	Beyond Air AITB	Filing · EDGAR
Mar 5, 2024	Form 4	Editas Medicine EDIT	Filing · EDGAR
Sep 20, 2023	Form 4	Bone Biologics	Filing · EDGAR
May 18, 2023	Form 4	Editas Medicine EDIT	Filing · EDGAR
May 18, 2023	Form 3	Editas Medicine EDIT	Filing · EDGAR
Apr 5, 2023	Form 4	SAB Biotherapeutics SABS	Filing · EDGAR
Apr 5, 2023	Form 3	SAB Biotherapeutics SABS	Filing · EDGAR
Mar 31, 2023	Form 4	Beyond Air AITB	Filing · EDGAR
Mar 20, 2023	Form 4	Beyond Air AITB	Filing · EDGAR
Mar 8, 2023	Form 4	Bone Biologics	Filing · EDGAR
Jan 19, 2023	Form 4	Aveo Pharmaceuticals	Filing · EDGAR
Mar 7, 2022	Form 4	Beyond Air AITB	Filing · EDGAR
Feb 28, 2022	Form 4	Bone Biologics	Filing · EDGAR
Feb 17, 2022	Form 4	Aveo Pharmaceuticals	Filing · EDGAR
Oct 21, 2021	Form 3	Bone Biologics	Filing · EDGAR
Apr 16, 2021	Form 4	Aveo Pharmaceuticals	Filing · EDGAR
Mar 8, 2021	Form 4	Beyond Air AITB	Filing · EDGAR
Mar 3, 2021	Form 4	Beyond Air AITB	Filing · EDGAR
Jan 8, 2020	Form 4	Aveo Pharmaceuticals	Filing · EDGAR
Jan 8, 2020	Form 3	Aveo Pharmaceuticals	Filing · EDGAR
Mar 8, 2019	Form 4	Valeritas Holdings	Filing · EDGAR
Nov 20, 2018	Form 4	Valeritas Holdings	Filing · EDGAR
Aug 15, 2018	Form 4	Beyond Air AITB	Filing · EDGAR
Apr 30, 2018	Form 4	Beyond Air AITB	Filing · EDGAR
Apr 30, 2018	Form 3	Beyond Air AITB	Filing · EDGAR
Feb 15, 2018	Form 4	Valeritas Holdings	Filing · EDGAR
May 23, 2017	Form 4	Valeritas Holdings	Filing · EDGAR
Mar 27, 2017	Form 4	Valeritas Holdings	Filing · EDGAR
Mar 24, 2017	Form 3	Valeritas Holdings	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 9:07 PM ET. The filing on SEC.gov is the record.